Financial Performance - The company's operating revenue for 2024 was CNY 2,018,333,771.81, a decrease of 15.07% compared to CNY 2,376,486,797.10 in 2023[23]. - The net profit attributable to shareholders for 2024 was CNY 74,075,384.59, representing an 81.34% decline from CNY 396,992,565.79 in 2023[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 23,573,407.86, down 93.02% from CNY 337,564,742.86 in 2023[23]. - The net cash flow from operating activities for 2024 was CNY 338,928,718.40, a decrease of 45.59% compared to CNY 622,875,138.44 in 2023[23]. - The total assets at the end of 2024 were CNY 9,396,152,610.45, a decrease of 6.29% from CNY 10,027,159,630.47 at the end of 2023[23]. - The net assets attributable to shareholders at the end of 2024 were CNY 8,078,818,586.72, down 2.42% from CNY 8,279,315,724.35 at the end of 2023[23]. - Basic earnings per share for 2024 were CNY 0.10, a decrease of 81.13% from CNY 0.53 in 2023[24]. - Diluted earnings per share for 2024 were also CNY 0.10, reflecting the same percentage decrease of 81.13% from CNY 0.53 in 2023[24]. - The weighted average return on net assets for 2024 was 0.91%, a decrease of 3.91 percentage points from 4.82% in 2023[24]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[8]. - The company has detailed potential risks in the report, which investors should be aware of[8]. - The company has a comprehensive risk statement regarding future plans and development strategies[7]. - The company faces risks from fluctuating international economic conditions, regulatory compliance, talent acquisition, and market competition, which could impact its business performance[149][151]. - The company emphasizes the importance of maintaining core competitive advantages amid increasing competition in the non-clinical CRO industry, which could affect profitability if not addressed[151]. Governance and Compliance - The company has received a standard unqualified audit report from KPMG Huazhen[5]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company is committed to improving its governance structure and ensuring transparent information disclosure to protect shareholder interests[153][158]. - The company has not reported any significant differences in governance compared to regulatory standards, indicating a stable governance framework[159]. - The company is committed to enhancing its governance practices in line with regulatory requirements, ensuring compliance with the China Securities Regulatory Commission[159]. Shareholder Relations - The company plans to distribute a cash dividend of 0.3 yuan per 10 shares to all shareholders, based on the total share capital after deducting repurchased shares[6]. - The total compensation for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to CNY 1,221.40 million[170]. - The company has established a robust communication platform for investor engagement, which has improved investor understanding of the company's operations[159]. - The company maintained a strong investor relations management strategy, enhancing transparency and communication with investors through various channels[159]. Research and Development - The company is focusing on enhancing its research capabilities and expanding its market presence in the pharmaceutical sector[16]. - The company aims to create a leading genetic resource and gene engineering technology platform for new drug development[80]. - The company has developed various ocular disease models and enhanced evaluation methods for ophthalmic drugs, addressing diverse market needs[40]. - The company has improved its drug evaluation methods for CNS drugs, establishing new administration methods and behavioral evaluation techniques[41]. - The company is committed to continuous innovation in drug evaluation technologies, particularly in non-clinical safety assessments[94]. Market Expansion and Strategy - The company plans to strengthen technology and business innovation despite the slowdown in market demand and intensified competition in the domestic pharmaceutical industry[35]. - The company aims to actively expand its customer base, with both the number of new customers and new signed projects showing growth[36]. - The company is exploring potential acquisitions to enhance its market position, with a budget of $50 million allocated for this purpose[163]. - The company plans to enhance its early clinical brand building by leveraging existing non-clinical business resources and expert team experience to provide precise clinical development strategies for innovative drug projects[145]. Operational Efficiency - The company has optimized its organizational structure and management systems to enhance operational efficiency and has built a professional service team of 2,652 members[56]. - The company has successfully reduced operational costs by 5%, improving overall profit margins[163]. - The company has implemented a salary policy based on performance, with salary increases tied to the company's operational performance[186]. - The company conducted over a thousand training sessions in 2024 to enhance employee skills and management capabilities[187]. Financial Management - The company reported a net cash outflow from investment activities of RMB -1,963,023,985.54, primarily due to increased purchases of financial products[110]. - The total R&D expenditure for the period was RMB 92,918,280.66, accounting for 4.60% of the operating revenue[124]. - The company has established a strict procurement management system to ensure the quality of experimental models and related supplies[74]. - The company has a robust cash dividend policy, ensuring compliance with the company charter and protecting minority shareholders' rights[191].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 附件為本公司於上海證券交易所網站刊登之 北京昭衍新藥研究中心股份有限公司 (1) 2024年度利潤分配方案的公告 (2) 2024年度社會責任報告 (3)關於變更公司註冊資本並修訂公司章程的公告 (4)關於對終止實施的員工持股計劃回購股份進行註銷的提示性公告 (5)關於調整2025年度關聯交易預計額度的公告 (6)內部控制審計報告 (7)內部控制評價報告 (8)第四屆監事會第十一次會議決議公告 ( ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 根據生仝智能服務框架協議修訂 截 至2025年12月31日止年度的持續關連交易年度上限 修訂截至2025年12月31日止年度的年度上限 茲提述本公司日期為2024年8月30日 有 關 生 仝 智 能 服 務 框 架 協 議 的 公 告。 鑑 於2024年 至2025年 若 干 軟 件 服 務 交 付 延 遲，導 致 預 計 於 截 至2025年12月31 日 止 年 度 向 生 仝 智 能 支 付 的 款 項 更 高；加 上 由 於 本 集 團 決 心 提 高 向 客 戶 提 供 服 務 的 效 率 及 準 確 性，於 截 至2025 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. (1)建 議 變 更 本 公 司 註 冊 股 本；及 (2)建議修訂組織章程細則 北京昭衍新藥研究中心股份有限公司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，於 第 四 屆 董 事 會 第 十 三 次 會 議 中，董 事 會 決 議 及 批 准（其 中 包 括）：(i) 建 議 變 更 本 公 司 註 冊 股 本；及(ii)建議修訂本公司組織章程細則（「組織章程細 則」）。 建議變更本公司註冊股本 由於公司已終止實施2021年 及2022年A股 員 工 持 股 計 劃，需 按 規 定 註 銷 回 購 證 券專用賬戶中部分A股股份及2022年員工持股計劃賬戶中的全部A股股份（合 計 129,114股），本 公 司 的 註 冊 股 本 及 本 公 司 的 股 ...

| 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 北京昭衍新藥研究中心股份有限公司 | | 股份代號 | 06127 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度之末期現金股息 | | 公告日期 | 2025年3月28日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 不適用 | | 宣派股息 | 每 股 0.03 RMB | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | HKD， 金額有待公佈 | | 匯率 | 有待公佈 | | 除淨日 | 有待公佈 | | 為符合獲取 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenue of RMB 2,018,334, a decrease of 15.1% compared to RMB 2,376,487 for the previous year[5] - Gross profit for the same period was RMB 505,540, down 48.4% from RMB 979,393 year-on-year[5] - Net profit for the year was RMB 69,755, reflecting an 82.2% decline from RMB 391,553 in the prior year[5] - Profit attributable to equity shareholders was RMB 74,075, a decrease of 81.3% compared to RMB 396,993 in the previous year[5] - The total comprehensive income for the year was RMB 18,714, significantly lower than RMB 396,514 in the previous year[6] - Basic and diluted earnings per share were both RMB 0.10, down from RMB 0.53 in the previous year[7] - The group's reported revenue for 2024 is RMB 2,336,043 thousand, a decrease from RMB 2,523,160 thousand in 2023, representing a decline of approximately 7.4%[20] - The gross profit for the reportable segments in 2024 is RMB 501,254 thousand, significantly lower than RMB 972,625 thousand in 2023, indicating a decrease of about 48.5%[21] - Revenue from external customers in China for 2024 is RMB 1,579,381 thousand, down from RMB 1,797,730 thousand in 2023, reflecting a decline of approximately 12.2%[22] - Revenue from external customers in the United States for 2024 is RMB 415,422 thousand, a decrease from RMB 566,271 thousand in 2023, representing a decline of about 26.6%[22] Assets and Liabilities - The company's total assets attributable to equity shareholders stood at RMB 8,078,818, down 2.4% from RMB 8,279,316[5] - Total non-current assets reached RMB 4,364,954 thousand, an increase of 50.3% from RMB 2,905,192 thousand in 2023[8] - Current liabilities totaled RMB 1,110,568 thousand, a decrease of 24.4% from RMB 1,467,365 thousand in 2023[8] - Net assets decreased to RMB 8,079,188 thousand, down 2.4% from RMB 8,281,041 thousand in 2023[9] - The company's equity attributable to shareholders decreased slightly to RMB 8,078,818 thousand from RMB 8,279,316 thousand in 2023[9] Expenses - Operating profit decreased to RMB 107,046, down from RMB 513,162 in the previous year[6] - Research and development expenses were RMB 92,918, slightly down from RMB 96,854 year-on-year[6] - The service cost for the year ended December 31, 2024, was RMB 1,512.8 million, an increase of 8.3% from RMB 1,397.1 million in 2023[65] - General and administrative expenses for the year ended December 31, 2024, were RMB 315.9 million, up 6.6% from RMB 296.5 million for the year ended December 31, 2023, maintaining relative stability[71] - Sales and marketing expenses for the year ended December 31, 2024, were RMB 27.9 million, an increase of 13.3% from RMB 24.6 million for the year ended December 31, 2023, primarily due to increased customer acquisition costs[70] Cash Flow and Investments - Cash and cash equivalents as of December 31, 2024, were RMB 965.2 million, a decrease of 66.3% from RMB 2,862.9 million as of December 31, 2023, primarily due to the purchase of financial assets measured at fair value[77] - The capital-to-debt ratio as of December 31, 2024, was 14.0%, down from 17.4% as of December 31, 2023, mainly due to a decrease in contract liabilities[78] - The company has raised approximately HKD 6,373.6 million (approximately RMB 5,285.2 million) from its global offering, net of underwriting commissions and other estimated expenses[92] - A total of RMB 2,061.3 million is allocated to expand the company's network and service capabilities in China, with significant projects in Guangzhou and Chongqing[98] Research and Development - The company continues to focus on expanding its contract research organization services, including non-clinical and clinical research[10] - The company has developed and optimized various ophthalmic disease models, meeting diverse market research and development needs[40] - The company has established systematic non-clinical evaluation methods for GLP-1R, GCGR, and GIPR target drugs, improving new drug development efficiency[43] - The company has established a comprehensive platform for drug discovery and development, covering various stages from antibody discovery to drug development, with capabilities to express antibodies at 300-500 mg scale[47] - The company is actively involved in the evaluation of gene therapy products, cell therapy products, and nucleic acid drugs, expanding its service capabilities[45] Future Plans and Strategies - By 2025, the company plans to increase investment in non-clinical services, improve service quality standards, and expand production capacity to solidify its market share[84] - The company aims to enhance its non-clinical drug evaluation services and expand upstream and downstream service capabilities, including early drug discovery and clinical CRO services[83] - The company plans to recruit and train high-end talents with international backgrounds to improve cross-cultural communication and service capabilities[86] - The company aims to enhance its international registration capabilities to meet overseas reporting demands, particularly in the US and China, assisting more new drug development enterprises in their product launch plans[88] Compliance and Governance - The audit committee has reviewed the financial statements for the year ending December 31, 2024, and confirmed compliance with relevant accounting standards and regulations[119] - The company's auditor, KPMG, has agreed that the financial figures in the preliminary announcement align with the audited consolidated financial statements for the year[120] - The annual report for 2024 will include all relevant information as per listing rules and will be published on the company's and Hong Kong Stock Exchange's websites[122]

Core Points - The company, JOINN LABORATORIES (CHINA) CO., LTD., was established on December 26, 2012, and is registered in the Beijing Economic and Technological Development Zone [2] - The company was approved by the China Securities Regulatory Commission (CSRC) to issue H shares on August 4, 2017, and subsequently listed on the Hong Kong Stock Exchange [2][3] - The registered capital of the company is RMB 749.34822 million [2][3] - The company aims to provide a new drug research and development technology platform for domestic and foreign enterprises, accelerating the industrialization of scientific and technological achievements [5] Company Structure - The company is a permanent joint-stock company, with all assets divided into equal shares, and shareholders are liable only to the extent of their subscribed shares [3] - The company has a total of 270,820,329 shares, with 63,035,301.4 million shares held by domestic investors, accounting for approximately 84.12% of the total share capital, and 11,899,520.6 million H shares held by foreign investors, accounting for approximately 15.88% [9] - The company can issue ordinary shares and, with approval, can also issue other types of shares [6][9] Share Issuance and Management - The company issues shares based on principles of openness, fairness, and justice, ensuring that each share of the same type has equal rights [6] - The company can increase its capital through various methods, including public offerings, private placements, and bonus shares [10] - The company has the right to repurchase its shares under specific circumstances, such as reducing registered capital or merging with other companies [11][12] Shareholder Rights - Shareholders have the right to receive dividends, attend and vote at shareholder meetings, supervise the company's operations, and transfer their shares [28] - The company must maintain a shareholder register that includes details of each shareholder and their respective shareholdings [22][25] - Shareholders can request the company to repurchase their shares if they disagree with resolutions made at shareholder meetings [28]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 馮宇霞 中 國，北 京 2025年3月14日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫 雲 霞 女 士、羅 樨 女 士 及 顧 靜 良 先 生，及 獨 立 非 執 行 董 事 張 帆 先 生、楊 福 全 先 生、陽 昌 雲 先 生 及 應 放 天 先 生。 北京昭衍新藥研究中心股份有限公司（「本公司」及其附屬公司統稱為「本集團」） 之董事會（「董事會」）兹通告謹定於2025年3月28日（星 期 五）舉 行 董 事 會 會 議，以 考慮及通過本集團截至2024年12月31日 止 的 年 度 業 績，考 慮 建 議 派 發 末 期 股 息 （如 有），以 及 處 理 其 他 事 項。 承董事會命 北京昭衍新藥研究中心股份有限公司 主 席 JOINN LABORAT ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 北京昭衍新药研究中心股份有限公司 关于以集中竞价交易方式回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 关于以集中竞价交易方式回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董事長 中 國 北 京，2025年2月 ...